Literature DB >> 24148623

Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect.

Kiran Kumar Velpula1, Arnima Bhasin, Swapna Asuthkar, Andrew J Tsung.   

Abstract

Glioblastoma multiforme is the most aggressive primary brain tumor in adults. Overexpression of the EGF receptor (EGFR) is recognized as a widespread oncogenic signature in glioblastoma multiforme, but the complexity of its contributions is not fully understood, nor the most effective ways to leverage anti-EGFR therapy in this setting. Hypoxia is known to drive the aggressive character of glioblastoma multiforme by promoting aerobic glycolysis rather than pyruvate oxidation carried out in mitochondria (OXPHOS), a phenomenon termed the Warburg effect, which is a general feature of oncogenesis. In this study, we report that hypoxia drives expression of the pyruvate dehydrogenase kinase (PDK1) and EGFR along with the hypoxia-inducing factor (HIF)-1α in human glioblastoma multiforme cells. PDK1 is a HIF-1-regulated gene and our findings indicated that hypoxia-induced PDK1 expression may promote EGFR activation, initiating a feed-forward loop that can sustain malignant progression. RNAi-mediated attenuation of PDK1 and EGFR lowered PDK1-EGFR activation and decreased HIF-1α expression, shifting the Warburg phenotype to OXPHOS and inhibiting glioblastoma multiforme growth and proliferation. In clinical specimens of glioblastoma multiforme, we found that immunohistochemical expression of PDK1, EGFR, and HIF-1α were elevated in glioblastoma multiforme specimens when compared with normal brain tissues. Collectively, our studies establish PDK1 as a key driver and candidate therapeutic target in glioblastoma multiforme. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24148623     DOI: 10.1158/0008-5472.CAN-13-1868

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  PDK1: a new therapeutic target for glioblastoma?

Authors:  Kiran Kumar Velpula; Andrew J Tsung
Journal:  CNS Oncol       Date:  2014-05

2.  PFKL/miR-128 axis regulates glycolysis by inhibiting AKT phosphorylation and predicts poor survival in lung cancer.

Authors:  Jie Yang; Jingqiu Li; Yanping Le; Chengwei Zhou; Shun Zhang; Zhaohui Gong
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

3.  Suppression of Resting Metabolism by the Angiotensin AT2 Receptor.

Authors:  Nicole K Littlejohn; Henry L Keen; Benjamin J Weidemann; Kristin E Claflin; Kevin V Tobin; Kathleen R Markan; Sungmi Park; Meghan C Naber; Francoise A Gourronc; Nicole A Pearson; Xuebo Liu; Donald A Morgan; Aloysius J Klingelhutz; Matthew J Potthoff; Kamal Rahmouni; Curt D Sigmund; Justin L Grobe
Journal:  Cell Rep       Date:  2016-07-28       Impact factor: 9.423

4.  Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal.

Authors:  Shulin Xiang; Robert T Dauchy; Adam Hauch; Lulu Mao; Lin Yuan; Melissa A Wren; Victoria P Belancio; Debasis Mondal; Tripp Frasch; David E Blask; Steven M Hill
Journal:  J Pineal Res       Date:  2015-04-20       Impact factor: 13.007

Review 5.  Elucidating immunometabolic targets in glioblastoma.

Authors:  Pooja Agarwal; Michael J Pajor; David M Anson; Maheedhara R Guda; Collin M Labak; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

Review 6.  Mitochondrial determinants of cancer health disparities.

Authors:  Aaheli Roy Choudhury; Keshav K Singh
Journal:  Semin Cancer Biol       Date:  2017-05-06       Impact factor: 15.707

7.  DINGO: differential network analysis in genomics.

Authors:  Min Jin Ha; Veerabhadran Baladandayuthapani; Kim-Anh Do
Journal:  Bioinformatics       Date:  2015-07-06       Impact factor: 6.937

Review 8.  Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas.

Authors:  Sean Mahase; Rachel N Rattenni; Pieter Wesseling; William Leenders; Clarissa Baldotto; Rajan Jain; David Zagzag
Journal:  Am J Pathol       Date:  2017-03-09       Impact factor: 4.307

Review 9.  Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment.

Authors:  Collin M Labak; Paul Y Wang; Rishab Arora; Maheedhara R Guda; Swapna Asuthkar; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

Review 10.  Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept.

Authors:  Carlen A Yuen; Swapna Asuthkar; Maheedhara R Guda; Andrew J Tsung; Kiran K Velpula
Journal:  CNS Oncol       Date:  2016-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.